Latest
PML
& Related Newswire
7/4/2006 8:07:00 AM | Increased Awareness of Alemtuzumab-Related Infections Urged 
=(0) A new study warns doctors that a drug currently used to treat certain types of leukemia and other blood disorders may be associated with more infectious side effects than previously thought. The drug, Campath (alemtuzumab), was associated with a variety of complications such as herpes infection, toxoplasmosis, progressive multifocal leukoencep...
Read More
6/5/2006 6:18:00 PM | Relapsing multiple sclerosis: FDA has approved the reintroduction ... =(0) The FDA has cautiously reapproved a controversial multiple sclerosis drug, Tysabri. The drug was withdrawn in February 2005 because of complications: some patients developed a rare brain infection called progressive multifocal leukoencephalopathy (PML) which caused severe disability or death. After months of study, the drug will soon be a...
Read More
4/28/2006 3:03:00 PM | MS drug Tysabri closer to EU launch =(0) The controversial Multiple Sclerosis drug Tysabri is a step closer to approval in the European Union. An advisory committee has recommended its use in certain cases of MS, as a stand-alone therapy (that is, not in combination with other drugs). No further cases of the deadly brain condition PML have been detected in Tysabri users. This co...
Read More
3/23/2006 3:03:00 AM | Ruling on MS Drug Tysabri Delayed =(0) A controversial drug for multiple sclerosis is not yet back on the market. Tysabri was available in the US for only three months when it was recalled due to concern that it was linked to cases of a rare brain disease, progressive multifocal leukoencephalopathy (PML). An FDA advisory panel recommends reinstatement in view of its success treating MS...
Read More
3/9/2006 5:07:00 PM | Tysabri Waltzes through FDA Advisory Panel by 12-0 Vote =(0) Sales of the Multiple Sclerosis drug Tysabri were suspended in February of 2005 when a number of patients taking the drug, along with a drug called Avonex developed progressive multifocal leukoencephalopathy a life threatening condition. Although the sales of Tysabri were suspended, the FDA convened an independent advisory panel that has unanimousl...
Read More
3/1/2006 5:07:00 PM | Evaluation of Patients Treated with Natalizumab for PML =(0) This is an abstract of an article from the New England Journal of Medecine, which examines the risk of developing progressive multifocal leukoencephalopathy (PML)in patients taking the drug natalizumab. The drug is used in the treatment of multiple sclerosis, Crohn's Disease and rheumatoid arthritis and has been linked with the development of the r...
Read More